Michigan Clinical Trials Report — June 2026

For Michiganders considering participation in clinical research, June 2026 presents a critical window of opportunity, particularly for trials nearing their conclusion. Across the state, 122 clinical trials are slated to close within the next 90 days, meaning time is running out to enroll. This includes 19 trials that are actively seeking healthy volunteers, offering a chance to contribute to medical science without a specific health condition.

Time is Short: Trials Nearing Completion

Individuals living with certain health conditions should act quickly to explore trials with impending deadlines. Research focusing on various cancers and heart conditions are among those with limited time remaining for enrollment. Conditions with trials closing soon include:

• Triple negative breast cancer
• Breast cancer
• Prostate cancer
• Advanced solid tumor
• Primary peritoneal cancer
• Heart failure
• Fallopian tube cancer
• Lung cancer
• Aortic regurgitation
• Aortic valve insufficiency

If you or someone you know is affected by these conditions, we encourage you to review these opportunities promptly. The chance to participate in these specific studies will soon pass.

Michigan's New Research Landscape: Major Studies and Diverse Opportunities

This month, Michigan welcomes 36 new clinical trials, a notable increase from the 29 trials that opened in May 2026. These new studies include several significant Phase 3 drug trials from major pharmaceutical companies, offering participants access to cutting-edge treatments for widespread health challenges like obesity, type 2 diabetes, and migraine, as well as crucial vaccine development.

• AstraZeneca is sponsoring NCT07667803, a Phase 3 "Master Protocol to Investigate Efficacy and Safety of Elecoglipron in Participants With Obesity or Overweight With or Without T2DM." This substantial global study aims to enroll 4,500 participants, evaluating a new treatment for weight management and type 2 diabetes.
• Another major Phase 3 trial, NCT07654361, is "Efficacy and Safety of Aleniglipron in Participants With Obesity or Overweight With a Weight-Related Comorbidity (ACCOMPLISH-1)," sponsored by Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics. This global study seeks 3,600 participants to assess the long-term efficacy and safety of aleniglipron.
• Pfizer is leading two important Phase 3 vaccine trials. NCT07629440, "A Study to Learn About How a New Pneumococcal Vaccine Works in Infants," aims for 3,230 participants to evaluate the safety and immune response of a new vaccine against pneumonia, meningitis, and otitis media in infants. Additionally, NCT07660198, "Study to Learn About Safety, Tolerability, and Immune Response of a Catch-up Pneumococcal Vaccine in Children and Adolescents," will enroll 1,200 participants to assess a new pneumococcal vaccine in older children.
• For those with type 2 diabetes, AstraZeneca is also sponsoring NCT07662213, a Phase 3 study to find out if the study drug elecoglipron helps adults with type 2 diabetes mellitus by comparing it with semaglutide, a medicine already used to treat the condition. This trial plans for 1,200 participants.
• Individuals experiencing migraines may be interested in NCT07645924, "A Study to Evaluate the Efficacy and Safety of Elismetrep (K-304) in the Acute Treatment of Migraine," a Phase 3 trial sponsored by Kallyope Inc., targeting 1,800 participants. Kallyope Inc. is also sponsoring NCT07674654, a long-term safety study of the same drug, aiming for 1,000 participants.
• A unique observational study, NCT07673016, sponsored by Convergent Genomics, Inc., is collecting specimens for the validation of UroAmp, a next-generation sequencing platform for the detection and surveillance of bladder cancer. This study seeks 2,500 participants.

The 36 new trials opening this month in Michigan cover a diverse range of health conditions, with a strong focus on metabolic health, pain management, and infectious disease prevention. The most common conditions addressed by these new studies include:

• Migraine (2 trials)
• Obesity (2 trials)
• Pneumococcal disease (2 trials)
• Chronic pain (2 trials)
• Overweight (2 trials)
• Type 2 diabetes mellitus (2 trials)

In terms of intervention types, drug trials lead the way, accounting for 17 of the new studies. Behavioral interventions are also well-represented with 6 new trials, alongside device and biological treatments.

Expanding Access: Where New Trials Are Opening

Michigan's clinical research landscape continues to be robust, with 2,130 clinical trials currently recruiting across 123 cities and 1,273 research sites statewide. This month, the majority of new research initiatives are concentrated in key metropolitan areas. Ann Arbor saw the highest number of new trials, with 18 opening, while Detroit followed with 7 new studies. Opportunities are also expanding in other parts of the state:

• Bay City (2 new trials)
• Southfield (2 new trials)
• Bingham Farms (2 new trials)
• Grand Rapids (2 new trials)
• Ypsilanti (1 new trial)
• Livonia (1 new trial)
• Royal Oak (1 new trial)
• Troy (1 new trial)

This distribution ensures that residents in various regions of Michigan have access to cutting-edge research, even as Ann Arbor and Detroit remain central hubs for clinical investigations.

Your Opportunity to Participate: Healthy Volunteers and Specific Demographics

For individuals without a specific medical condition, there are significant opportunities to contribute to medical science. Of the 36 new trials launched this month, 6 are actively seeking healthy volunteers. Statewide, a total of 164 trials are currently recruiting healthy participants, providing numerous avenues for those interested in supporting medical research.

Clinical trials in Michigan are designed to be inclusive, with a broad range of eligibility criteria. Of the new trials, 3 include children as participants, and 31 include older adults, ensuring that research benefits diverse age groups. Academic institutions continue to play a vital role in the state's research ecosystem, with the University of Michigan sponsoring 9 of the new trials, and the University of Michigan Rogel Cancer Center sponsoring 3. Industry sponsors are also driving significant research efforts, with 17 new trials sponsored by pharmaceutical companies such as AstraZeneca, Pfizer, Eli Lilly and Company, and Kallyope Inc.

As we move through June, the focus will remain on the ongoing enrollment in these significant Phase 3 trials and the exploration of new treatments, diagnostics, and preventive measures for a broad spectrum of health challenges across Michigan.